Matthews, North Carolina – CEM Corporation, a leading global provider of microwave laboratory instrumentation, is pleased to announce that its patent claims for the microwave peptide synthesis process have now been allowed in Europe by the European Patent Office. The allowed application contains broad claims regarding the process of using microwave energy to accelerate two key steps in performing almost all solid phase peptide synthesis, deprotection and coupling. It also covers the process of performing Fmoc and Boc chemistries, the two most common strategies employed in peptide synthesis.

“We are very excited to see our first claims accepted in Europe and we’re looking forward to the acceptance of additional patents we have filed in Europe and Asia,” said Michael J. Collins, president & CEO of CEM Corporation. “Microwave technology has seen wide acceptance in the scientific community since we first introduced microwave peptide synthesizers in 2003. Our Liberty™ Systems have become the best-selling automatic peptide synthesizers on the market and continue to be a powerful driver for growth for CEM.”

Microwave technology is the fastest growing method for peptide synthesis. It allows research scientists to make higher quality peptides faster than ever before. CEM’s proprietary microwave peptide synthesis process also enables the production of longer, more difficult peptides that were not possible to produce using conventional techniques.

About CEM

CEM Corporation, a private company based in Matthews, North Carolina, is a leading provider of microwave laboratory instrumentation. The Company has subsidiaries in the United Kingdom, Germany, Italy and France, as well as a global network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The Company’s products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research.